|1.||Song, Soo-Chang: 6 articles (07/2013 - 09/2009)|
|2.||Cho, Jung-Kyo: 3 articles (07/2013 - 05/2011)|
|3.||Hong, Ki-Yun: 3 articles (05/2011 - 09/2009)|
|4.||Yang, Han-Kwang: 2 articles (07/2013 - 05/2011)|
|5.||Kuh, Hyo-Jeong: 2 articles (01/2013 - 02/2010)|
|6.||Chun, Changju: 2 articles (03/2012 - 09/2009)|
|7.||Hong, Ji Min: 1 article (07/2013)|
|8.||Han, Taesu: 1 article (07/2013)|
|9.||Lee, Jaehwi: 1 article (01/2013)|
|10.||Lee, Joo-Ho: 1 article (01/2013)|
01/01/2013 - "Overall, poly(organophosphazene) represents a novel thermosensitive DDS for intratumoral delivery of PTX, which can accommodate a large dose of the drug in addition to reducing its systemic exposure by restricting biodistribution to tumor tissue alone."
01/01/2013 - "We also investigated the tumor pharmacokinetics of PTX (60 mg/kg) when administered as an intratumoral injection using poly(organophosphazene) in mice with human tumor xenografts. "
01/01/2013 - "Here, we evaluated the penetration kinetics of PTX released from the PTX-poly(organophosphazene) hydrogel mixture in multicellular layers (MCLs) of human cancer cells. "
02/25/2010 - "In this study, we evaluated the pharmacokinetics of DOX (30 mg/kg) when given as an intratumoral injection using poly(organophosphazene) hydrogel in mice with human gastric tumor xenografts. "
09/01/2009 - "Based on the in vivo antitumor activities of the locally injected poly(organophosphazene)-DOX conjugate into the tumor-induced nude mice, the conjugate hydrogel after the local injection at the tumor site was shown to inhibit tumor growth more effectively with less toxicity and much longer than doxorubicin and saline as controls, indicating that tumor active DOX from the conjugate hydrogel is released slowly over a longer period of time and effectively accumulated locally in the tumor sites. "
|2.||Breast Neoplasms (Breast Cancer)
|1.||Heterologous Transplantation (Xenotransplantation)